Characterization of Doxorubicin Unknown Impurity using 1D-NMR (1H)

被引:0
作者
Somepally, Sridevi [1 ]
Goh, Khang Wen [2 ]
Bollikolla, Hari Babu [1 ,3 ]
机构
[1] Acharya Nagarjuna Univ, Dept Chem, N Nagar 522510, Andhra Pradesh, India
[2] INTI Int Univ, Fac Data Sci & Informat Technol, Nilai 71800, Malaysia
[3] Andhra Kesari Univ, Dept Chem, Ongole 523001, Andhra Pradesh, India
来源
EGYPTIAN JOURNAL OF CHEMISTRY | 2024年 / 67卷 / 09期
关键词
Doxorubicin; RRT impurity 1.26; 1D-NMR (1H); LC-MS mass ionization; Structure elucidation;
D O I
10.21608/EJCHEM.2024.249648.8892
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Doxorubicin, an anthracyline medication, is regularly used to treat a number of malignancies, including sarcoma, lung, breast, gastric, thyroid, non-Hodgkin's lymphoma, ovarian, Hodgkin's lymphoma, multiple myeloma, and childhood cancers. One unidentified doxorubicin impurity with an RRT of 1.23 and a concentration higher than 0.1% was discovered during the quality inspection of doxorubicin in bulk forms. By thoroughly analysing the 1D-NMR (1H) spectroscopic data and the LCMS mass ionization spectrum data, the structure and molecular mass of the unknown doxorubicin impurity with an RRT of 1.23 were determined. From spectroscopic data and the LC-MS mass ionization spectrum data, it was also observed that doxorubicin and unknown doxorubicin impurity with an RRT of 1.23 are interconvertible.
引用
收藏
页码:151 / 157
页数:7
相关论文
共 10 条
  • [1] Determination of genotoxic impurity in atazanavir sulphate drug substance by LC-MS
    Bhavani, K. Geetha
    Krishna, K. Bala Murali
    Srinivasu, N.
    Ramachandran, D.
    Raman, N. V. V. S. S.
    Babu, B. Hari
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2017, 132 : 156 - 158
  • [2] Impurities In New Drug Products Q3B (R2), 2006, ICH Harmonised Tripartite Guideline,
  • [3] Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree?
    Kalyanaraman, Balaraman
    [J]. REDOX BIOLOGY, 2020, 29
  • [4] Kaushik Dheeraj, 2015, J Pharm Anal, V5, P285, DOI 10.1016/j.jpha.2015.05.003
  • [5] Oxidized phospholipids in Doxorubicin-induced cardiotoxicity
    Koleini, Navid
    Nickel, Barbara E.
    Edel, Andrea L.
    Fandrich, Robert R.
    Ravandi, Amir
    Kardami, Elissavet
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2019, 303 : 35 - 39
  • [6] Contemporary best practice in the use of neoadjuvant chemotherapy in muscle-invasive bladder cancer
    Marcq, Gautier
    Jarry, Edouard
    Ouzaid, Idir
    Hermieu, Jean-Francois
    Henon, Francois
    Fantoni, Jean-Christophe
    Xylinas, Evanguelos
    [J]. THERAPEUTIC ADVANCES IN UROLOGY, 2019, 11 : 1 - 8
  • [7] Determination of enantiomer impurity in Bortezomib lyo injection formulation by using normal-phase liquid chromatography
    Najana, Sanni Babu
    Bollikolla, Hari Babu
    [J]. FUTURE JOURNAL OF PHARMACEUTICAL SCIENCES, 2021, 7 (01)
  • [8] A comprehensive review on time-tested anticancer drug doxorubicin
    Sritharan, Sruthi
    Sivalingam, Nageswaran
    [J]. LIFE SCIENCES, 2021, 278
  • [9] Current state of the art and emerging pharmacotherapy for uterine leiomyosarcomas
    Tantari, Matteo
    Barra, Fabio
    Di Domenico, Stefano
    Ferraioli, Domenico
    Vellone, Valerio Gaetano
    De Cian, Franco
    Ferrero, Simone
    [J]. EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (06) : 713 - 723
  • [10] Cardiac Magnetic Resonance and Cardio-Oncology Does T2 Signal the End of Anthracycline Cardiotoxicity?
    Yu, Anthony F.
    Chan, Angel T.
    Steingart, Richard M.
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (07) : 792 - 794